ARVN
Price
$7.95
Change
+$0.05 (+0.63%)
Updated
Jul 3 closing price
Capitalization
580.28M
24 days until earnings call
GMAB
Price
$20.30
Change
-$0.14 (-0.68%)
Updated
Jul 3 closing price
Capitalization
12.61B
32 days until earnings call
Interact to see
Advertisement

ARVN vs GMAB

Header iconARVN vs GMAB Comparison
Open Charts ARVN vs GMABBanner chart's image
Arvinas
Price$7.95
Change+$0.05 (+0.63%)
Volume$826.66K
Capitalization580.28M
Genmab A/S ADS
Price$20.30
Change-$0.14 (-0.68%)
Volume$1.13M
Capitalization12.61B
ARVN vs GMAB Comparison Chart in %
Loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARVN vs. GMAB commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a Hold and GMAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (ARVN: $7.95 vs. GMAB: $20.30)
Brand notoriety: ARVN and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 32% vs. GMAB: 75%
Market capitalization -- ARVN: $580.28M vs. GMAB: $12.6B
ARVN [@Biotechnology] is valued at $580.28M. GMAB’s [@Biotechnology] market capitalization is $12.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 1 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).

  • ARVN’s FA Score: 1 green, 4 red.
  • GMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, GMAB is a better buy in the long-term than ARVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 5 TA indicator(s) are bullish while GMAB’s TA Score has 3 bullish TA indicator(s).

  • ARVN’s TA Score: 5 bullish, 2 bearish.
  • GMAB’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ARVN is a better buy in the short-term than GMAB.

Price Growth

ARVN (@Biotechnology) experienced а +1.92% price change this week, while GMAB (@Biotechnology) price change was -2.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ARVN is expected to report earnings on Jul 31, 2025.

GMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($12.6B) has a higher market cap than ARVN($580M). GMAB YTD gains are higher at: -2.731 vs. ARVN (-58.529). GMAB has higher annual earnings (EBITDA): 1.35B vs. ARVN (-89.3M). GMAB has more cash in the bank: 3.23B vs. ARVN (954M). ARVN has less debt than GMAB: ARVN (10.5M) vs GMAB (143M). GMAB has higher revenues than ARVN: GMAB (3.12B) vs ARVN (427M).
ARVNGMABARVN / GMAB
Capitalization580M12.6B5%
EBITDA-89.3M1.35B-7%
Gain YTD-58.529-2.7312,143%
P/E RatioN/A11.91-
Revenue427M3.12B14%
Total Cash954M3.23B30%
Total Debt10.5M143M7%
FUNDAMENTALS RATINGS
ARVN vs GMAB: Fundamental Ratings
ARVN
GMAB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8642
PRICE GROWTH RATING
1..100
6361
P/E GROWTH RATING
1..100
10093
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (18) in the Biotechnology industry is somewhat better than the same rating for GMAB (58) in the null industry. This means that ARVN’s stock grew somewhat faster than GMAB’s over the last 12 months.

ARVN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that ARVN’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (42) in the null industry is somewhat better than the same rating for ARVN (86) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than ARVN’s over the last 12 months.

GMAB's Price Growth Rating (61) in the null industry is in the same range as ARVN (63) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.

GMAB's P/E Growth Rating (93) in the null industry is in the same range as ARVN (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNGMAB
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
60%
Momentum
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
68%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
72%
Bearish Trend 4 days ago
71%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 27 days ago
62%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 4 days ago
68%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
80%
Aroon
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
57%
View a ticker or compare two or three
Interact to see
Advertisement
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LIVR27.160.26
+0.97%
Intelligent Livermore ETF
TSPA39.370.31
+0.79%
T. Rowe Price US Equity Research ETF
INOV32.250.04
+0.11%
Innovator Intl Dev Pwr Bffr ETF - Nov
TAIL11.88-0.06
-0.46%
Cambria Tail Risk ETF
NAIL58.36-3.10
-5.04%
Direxion Daily Hmbldrs&Supls Bull 3X ETF

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with ERAS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+0.63%
ERAS - ARVN
39%
Loosely correlated
-0.69%
GMAB - ARVN
38%
Loosely correlated
-0.68%
TECH - ARVN
37%
Loosely correlated
-0.08%
CRGX - ARVN
36%
Loosely correlated
+1.36%
ARCT - ARVN
36%
Loosely correlated
+1.17%
More

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with ARGX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-0.68%
ARGX - GMAB
40%
Loosely correlated
-0.30%
ARVN - GMAB
38%
Loosely correlated
+0.63%
TECH - GMAB
37%
Loosely correlated
-0.08%
BMRN - GMAB
37%
Loosely correlated
N/A
IMCR - GMAB
37%
Loosely correlated
+0.82%
More